These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 19491086)

  • 41. [Safety of adjuvant dose-dense chemotherapy with paclitaxel and epirubicin for high-risk breast cancer].
    Wu WH; Li Q; Xu BH; Zhang P; Zhao LM; Yuan P; Wang JY; Cai RG; Zhou AP
    Zhonghua Zhong Liu Za Zhi; 2008 Jul; 30(7):548-51. PubMed ID: 19062727
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer.
    Dang CT; D'Andrea GM; Moynahan ME; Dickler MN; Seidman AD; Fornier M; Robson ME; Theodoulou M; Lake D; Currie VE; Hurria A; Panageas KS; Norton L; Hudis CA
    Clin Cancer Res; 2004 Sep; 10(17):5754-61. PubMed ID: 15355903
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
    Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
    Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The safety of docetaxel with cyclophosphamide (TC) therapy as adjuvant chemotherapy for Japanese women with operable breast cancer].
    Tashiro H; Sagawa T; Okada K; Kurokawa T; Soga H; Watanabe R; Yasuoka Y; Honda K; Watanabe Y; Gangi J; Akehi S; Masuda J; Nomoto M;
    Gan To Kagaku Ryoho; 2007 Mar; 34(3):393-6. PubMed ID: 17353630
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.
    Peters WP; Rosner GL; Vredenburgh JJ; Shpall EJ; Crump M; Richardson PG; Schuster MW; Marks LB; Cirrincione C; Norton L; Henderson IC; Schilsky RL; Hurd DD
    J Clin Oncol; 2005 Apr; 23(10):2191-200. PubMed ID: 15767638
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Febrile neutropenia and role of prophylactic granulocyte colony-stimulating factor in docetaxel and cyclophosphamide chemotherapy for breast cancer.
    Kimura Y; Sasada S; Emi A; Masumoto N; Kadoya T; Okada M
    Support Care Cancer; 2021 Jul; 29(7):3507-3512. PubMed ID: 33146835
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Feasibility study of docetaxel and cyclophosphamide six- cycle therapy as adjuvant chemotherapy for Japanese human epidermal growth factor receptor 2-negative breast cancer patients.
    Abe H; Mori T; Kawai Y; Tomida K; Kubota Y; Umeda T; Tani T
    Asian Pac J Cancer Prev; 2013; 14(8):4835-8. PubMed ID: 24083754
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: results of an observational study.
    Freyer G; Campone M; Peron J; Facchini T; Terret C; Berdah JF; Jacquin JP; Coeffic D; Hilaire Pde S; Falandry C
    Crit Rev Oncol Hematol; 2011 Dec; 80(3):466-73. PubMed ID: 21565521
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety Analysis of Adjuvant Chemotherapy with Docetaxel Administered with or without Anthracyclines to Early Stage Breast Cancer Patients: Combined Results from the Asia- Pacific Breast Initiatives I and II.
    Kim SB; Sayeed A; Villalon AH; Shen ZZ; Yau TK; Shah MA; Hou MF; Thuan TV; Ba DN; Chao TY
    Asian Pac J Cancer Prev; 2016; 17(2):697-702. PubMed ID: 26925666
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Safety and tolerance of docetaxel (especially 75 mg/m2) with cyclophosphamide (TC therapy) as adjuvant chemotherapy for Japanese patients with operable breast cancer].
    Watanabe K; Taguchi K; Yamamoto M; Jotoku H; Tamura M
    Gan To Kagaku Ryoho; 2010 Jul; 37(7):1265-9. PubMed ID: 20647707
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Feasibility of adjuvant docetaxel plus cyclophosphamide therapy for breast cancer].
    Naito K; Oura S; Yoshimasu T; Nakamura R; Hirai Y; Kiyoi M; Miyasaka M; Okamura Y
    Gan To Kagaku Ryoho; 2010 Oct; 37(10):1913-6. PubMed ID: 20948255
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study.
    Burkard ME; Wisinski KB; Njiaju UO; Donohue S; Hegeman R; Stella A; Mansky P; Shah V; Goggins T; Qamar R; Dietrich L; Kim K; Traynor AM; Tevaarwerk AJ
    Clin Breast Cancer; 2014 Jun; 14(3):205-11. PubMed ID: 24342730
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adjuvant Docetaxel and Cyclophosphamide (DC) with prophylactic granulocyte colony-stimulating factor (G-CSF) on days 8 &12 in breast cancer patients: a retrospective analysis.
    Yerushalmi R; Goldvaser H; Sulkes A; Ben-Aharon I; Hendler D; Neiman V; Ciuraru NB; Bonilla L; Amit L; Zer A; Granot T; Rizel S; Stemmer SM
    PLoS One; 2014; 9(10):e107273. PubMed ID: 25330205
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Toxicity and quality of life of Korean breast cancer patients treated with docetaxel-containing chemotherapy without primary G-CSF prophylaxis.
    Lee J; Ahn MH; Jang YH; Lee EJ; Park JH; Rho J; Kim Z; Kim HM; Han SW; Lim C; Lee MH; Kim SY
    Breast Cancer; 2014 Nov; 21(6):670-6. PubMed ID: 23371824
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Safety and tolerability of docetaxel with cyclophosphamide for early breast cancer].
    Kawabata H; Iwatani T; Makuuchi R; Miura D; Suzuki N; Nakazawa H
    Gan To Kagaku Ryoho; 2010 May; 37(5):835-9. PubMed ID: 20495312
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Tolerability and safety of docetaxel plus cyclophosphamide as adjuvant chemotherapy for axillary lymph node-negative breast cancer--JECBC04 trial].
    Yamamoto N; Tabei T; Inoue K; Takei H; Sato N; Yanagita Y; Fujisawa T; Fujii H; Saeki T; Kurosumi M
    Gan To Kagaku Ryoho; 2010 Jan; 37(1):57-63. PubMed ID: 20087033
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of an electronic tool in prescribing primary prophylaxis with ciprofloxacin or granulocyte colony-stimulating factor for breast cancer patients receiving TC chemotherapy.
    Sulpher J; Giguere P; Hopkins S; Dent S
    Support Care Cancer; 2016 Jul; 24(7):3185-9. PubMed ID: 26939922
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Subjective and objective assessment of edema during adjuvant chemotherapy for breast cancer using taxane-containing regimens in a randomized controlled trial: The National Surgical Adjuvant Study of Breast Cancer 02.
    Ohsumi S; Shimozuma K; Ohashi Y; Takeuchi A; Suemasu K; Kuranami M; Ohno S; Watanabe T
    Oncology; 2012; 82(3):131-8. PubMed ID: 22433221
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Comparison of the Incidence of Febrile Neutropenia in Doxorubicin/Cyclophosphamide(AC)and Docetaxel/Cyclophosphamide(TC) Perioperative Chemotherapies for Primary Breast Cancer].
    Nohara Y; Ono S; Tanaka M; Yoshinaga Y; Ito T; Yamashita S; Iwasaki A
    Gan To Kagaku Ryoho; 2020 Nov; 47(11):1589-1591. PubMed ID: 33268733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.